Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12851728 | 1.00 | CHRM2 (0.35) | CHRM2CHRM4CHRM3KMT2AL3MBTL1 | |
| SCHEMBL12305086 | 1.00 | CHRM2 (0.35) | CHRM2CHRM4CHRM3KMT2AL3MBTL1 | |
| Hydrochloric Acid SCHEMBL30172522 | 0.98 | CHRM2 (0.34) | CHRM2CHRM4CHRM3KMT2AL3MBTL1 | |
| SCHEMBL6087794 | 0.90 | CHRM2 (0.40) | CHRM2CHRM4CHRM3KMT2AL3MBTL1 | |
| SCHEMBL25867321 | 0.90 | CHRM2 (0.40) | CHRM2CHRM4CHRM3KMT2AL3MBTL1 | |
| SCHEMBL12253527 | 0.84 | ALDH1A1 (0.36) | L3MBTL1SMN1; SMN2 | |
| SCHEMBL30270308 | 0.84 | ALDH1A1 (0.33) | CHRM2CHRM4CHRM3KMT2A | |
| SCHEMBL1517868 | 0.83 | L3MBTL1 (0.33) | L3MBTL1SMN1; SMN2 | |
| SCHEMBL12034082 | 0.83 | L3MBTL1 (0.33) | L3MBTL1SMN1; SMN2 | |
| SCHEMBL1518056 | 0.83 | L3MBTL1 (0.33) | L3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023133336-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| US-8013170-B2 | Substituted pyrrolo[1,2-d][1,4]-diazonines and treatment of brain damage | NEUREN PHARMACEUTICALS LIMITED (AU) | 2011-09-06 | — | — | US | disclosed |
| US-20110052528-A1 | Neuroprotective macrocyclic compounds and methods for their use | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2011-03-03 | — | — | US | disclosed |
| US-7485630-B2 | Neuroprotective macrocyclic compounds and methods for their use | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2009-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110052528-A1 | Neuroprotective macrocyclic compounds and methods for their use | NLN, BAD, BDNF | CHRM2 1807/4885CHRM4 1392/4885CHRM3 1383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.